In May, Governor Rick Perry, joined by Texas A&M University System Chancellor Michael D. McKinney, M.D., and University of Texas System Chancellor Francisco G. Cigarroa, M.D., announced a major cancer research initiative between the institutions. The new collaboration will combine the resources of the A&M System’s National Center for Therapeutic Manufacturing and UT’s MD Anderson Cancer Center to develop new cancer-fighting drugs and accelerate the process of getting new cancer treatments to patients.
The NCTM is the state of Texas’ core biological pharmaceutical manufacturing, research and education facility, now in construction on the Texas A&M University campus. Once complete, researchers from both university systems will utilize the NCTM’s first-in-class resources to produce vaccines and therapies for clinical use in the fight against cancer.
Through this agreement, MD Anderson will become a longterm partner and collaborator of the NCTM, increasing the ability of researchers from its laboratories to quickly provide important new cancer vaccines and treatments, including vaccines targeted to specific individuals. MD Anderson’s leadership will be integrally involved in the NCTM’s design, including the development of a cancer research core made possible by the state-of-the-art therapeutics capabilities of the site’s modular clean room “pods.” MD Anderson also will be a vital member of the NCTM’s scientific board, and the two institutions will collaborate on future grant and funding initiatives to advance cancer research.